Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 232,609 |
|
|||||
| News | - | ||||||
| Day High | 17.26 | Low High |
|||||
| Day Low | 16.17 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Celcuity Inc | CELC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.85 | 5.19% | 17.24 | 17:30:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 16.22 | 16.17 | 17.26 | 17.24 | 16.39 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,752 | 232,609 | $ 16.66 | $ 3,876,206 | - | 8.389 - 22.188 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:03:07 | 75 | $ 17.24 | USD |
Celcuity Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 417.26M | 24.20M | - | 0 | -63.78M | -2.64 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Celcuity News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CELC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 19.60 | 19.60 | 16.17 | 17.44 | 148,113 | -2.36 | -12.04% |
| 1 Month | 17.48 | 22.188 | 16.17 | 19.40 | 208,088 | -0.24 | -1.37% |
| 3 Months | 14.82 | 22.188 | 13.74 | 17.65 | 221,175 | 2.42 | 16.33% |
| 6 Months | 9.55 | 22.188 | 9.36 | 16.32 | 165,078 | 7.69 | 80.52% |
| 1 Year | 10.06 | 22.188 | 8.389 | 14.40 | 121,532 | 7.18 | 71.37% |
| 3 Years | 26.10 | 33.01 | 4.81 | 14.64 | 83,463 | -8.86 | -33.95% |
| 5 Years | 20.65 | 33.01 | 4.03 | 16.39 | 73,261 | -3.41 | -16.51% |
Celcuity Description
| Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR). |
